

# Center for Controlled Chemical Delivery

Distinguished Center

Dr. Sung Wan Kim/University of Utah/SLC, Utah

Established as a center in 1986. A world leader in drug delivery systems, this center is developing innovative delivery systems for pharmaceutical and chemical agents. One of their spin-off companies recently announced a multi-million dollar research contract with Syntex, a multi-billion dollar in sales U.S. pharmaceutical company. Researchers are working on oral delivery systems for insulin that will promote absorption. Additional systems are being designed for the continuous release of drugs for anti-hypertensive and anti-cancer therapy. Received "Distinguished Center" status in 1991.

Overview	Technologies	Status	Economic Impact
<p>Current State Contract \$100,000</p> <p>FY92 Matching Funds \$1,489,257</p> <p>Cumulative . . . . . \$10,661,063</p> <p>Total Jobs Created . . . . . 131</p> <p>Industry . . . . . 89</p> <p>Center . . . . . 42</p> <p>Direct Center Spin-offs . . . . . 1</p> <p>Total Benefiting Utah Companies 3</p> <p>License Agreements . . . . . 4</p> <p>Patents Applied . . . . . 14</p> <p>Patents Issued . . . . . 2</p>	<ul style="list-style-type: none"> <li>* Membrane transport</li> <li>* Novel hydrogels</li> <li>* Polymeric surfactants</li> <li>* Macromolecular drugs</li> <li>* Heparin removal filters</li> <li>* Insulin delivery systems</li> <li>* Design of nonthrombogenic surfaces</li> <li>* Oral delivery of peptides (insulin)</li> <li>* Biodegradable polymeric prodrugs</li> <li>* Colon targeting</li> <li>* Targetable anti-cancer systems</li> </ul>	<ul style="list-style-type: none"> <li>* Heparin removal filters are being developed as a disposable system to remove excessive amounts of heparin from circulating blood</li> <li>* Research continues on the self-regulated insulin delivery system</li> <li>* Sponsors international symposium on drug delivery systems every other year</li> <li>* Nine patents licensed to two Utah companies</li> <li>* Over 50 researchers toured CCCD facilities to discuss future research collaboration and joint research</li> </ul>	<ul style="list-style-type: none"> <li>* Spin-off TheraTech, Inc. has 60 employees with \$3.5 M in sales in 1992</li> <li>* Successful 9M IPO in 1991</li> <li>* New spin-off company, Insutech, Inc. formed to specialize in insulin delivery systems</li> <li>* TTI will begin marketing a female hormone patch, est. \$5 million first year</li> <li>* Research Medical, another Utah company, is developing a heparin filter based on center technology which should produce sales of \$50 million/year</li> </ul>

H:\home\and\wp\leglat\cont.lbg